Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
4.620
-0.090 (-1.91%)
Oct 29, 2025, 4:00 PM EDT - Market closed
Neuphoria Therapeutics Revenue
In the fiscal year ending June 30, 2025, Neuphoria Therapeutics had annual revenue of $15.65M. Neuphoria Therapeutics had revenue of $-13.27K in the quarter ending June 30, 2025.
Revenue (ttm)
$15.65M
Revenue Growth
n/a
P/S Ratio
0.49
Revenue / Employee
$1,956,181
Employees
8
Market Cap
10.89M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 15.65M | - | - |
| Jun 30, 2024 | - | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 4.17M | 3.48M | 499.60% |
| Jun 30, 2021 | 695.81K | -1.37M | -66.32% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
NEUP News
- 1 day ago - Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process - GlobeNewsWire
- 8 days ago - PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 8 days ago - Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder - GlobeNewsWire
- 4 weeks ago - Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates - GlobeNewsWire
- 7 weeks ago - Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD) - GlobeNewsWire
- 2 months ago - Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 5 months ago - Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting - GlobeNewsWire
- 5 months ago - Neuphoria Provides First Quarter 2025 Business Updates - GlobeNewsWire